Xylitol Nasal Spray Prevents SARS-CoV-2 Infection

By Editorial Team -
The sophisticated American consumer has grown accustomed to the gold-standard for drug and health products—the prospective Randomized, double-blind, placebo-Controlled Trial (RCT). Operation Warp Speed (OWS) was supposed to be a churning mill of large RCT’s to help the nation understand what conclusively is effective in the prevention and treatment of COVID-19. Unfortunately, after three years, has delivered failed products (remdesivir, baricitinib, molnupiravir, COVID-19 vaccines) and small inconclusive trials of products that doctors have found effective in practice including off-target generic antivirals and anticoagulants. OWS did not test simple, affordable, available prevention strategies. Fortunately such RCTs where done outside of the US and have brought us important findings.

Balmforth et al, conducted a prospective double-blind, placebo-controlled trial of a xylitol based nasal spray in the prevention of SARS-CoV-2 infection in exposed healthcare workers in two hospitals in Uttar Pradesh, India. Xylitol is known to have anti-infective and anti-inflammatory properties and is used in XLEAR nasal spray and anti-infective chewing gum to prevent dental caries. Balmforth found that SARS-CoV-2 infection confirmed by serology was 71% lower with xylitol compared to placebo [36 cases (13.1%) Vs 97 cases (34.5%); odds ratio [OR] 0.29 (95% CI; 0.18–0.45), p < 0.0001]. Fewer clinical symptoms were also seen in the test group [57 cases (17.6%) vs 112 cases (34.6%); OR 0.40, (95% CI; 0.27–0.59), p < 0.0001]. No harmful effects were associated with xylitol. 

A smaller study of xylitol nasal spray in mild COVID-19 cases demonstrated that persistent loss of smell may be eliminated with xylitol nasal spray during the acute congestion phase.



Balmforth D, Swales JA, Silpa L, Dunton A, Davies KE, Davies SG, Kamath A, Gupta J, Gupta S, Masood MA, McKnight Á, Rees D, Russell AJ, Jaggi M, Uppal R. Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial. J Clin Virol. 2022 Oct;155:105248. doi: 10.1016/j.jcv.2022.105248. Epub 2022 Jul 25. PMID: 35952426; PMCID: PMC9313533.

I have been impressed with the RCTs of topical nasal sprays and gargles in COVID-19 far more than those with oral or intravenous drugs. Xylitol available as XLEAR in US pharmacies is one of several choices for local nasopharyngeal protection and treatment of COVID-19.

Sources and References:

Reposted from Peter A. McCullough’s Substack.

Related: Best Nasal Sprays for COVID-19

Comments

Post a Comment

Pages

Popular posts from this blog

AI Wearable Technology Innovations 2025–2026: Health, Fitness & Beyond

By -
Image
Artificial intelligence (AI) is redefining what wearable technology can do. In 2025 and heading into 2026, wearables are no longer passive tracking devices — they are becoming intelligent, predictive, and deeply personalized health and lifestyle companions. Source:  Grand View Research From smart rings and AI fitness coaches to augmented reality glasses and skin-integrated sensors, AI-powered wearables are transforming healthcare, wellness, productivity, and human-machine interaction. 1. AI-Driven Health Monitoring and Early Detection Advanced AI algorithms are dramatically improving the accuracy of wearable health sensors. Machine learning models filter noise, personalize baselines, and detect anomalies related to heart rhythm, blood oxygen, stress, and sleep. Modern wearables now approach clinical-grade monitoring, enabling early detection of conditions such as arrhythmias, sleep disorders, and metabolic stress — a major step toward preventive healthcare. Best AI Smart Ring: ...
Read more

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies (March 2026 Version)

By -
Image
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Updated Analysis as of March 2026 Fast-forward to March 9, 2026, and the correlation has flipped dramatically positive amid renewed volatility. The 30-day correlation coefficient between Bitcoin and the S&P 500 (closely tied to Nasdaq trends) stands at 0.74, the highest level this year. Similarly, Bitcoin's correlation with the Nasdaq has swung from -0.68 in early February to +0.72, highlighting sensitivity to risk-off flows and macro events like geopolitical tensions. Bitcoin remains strongly aligned with the Nasdaq 100, showing little correlation with gold or bonds, reinforcing its role as a risk asset rather than a safe haven. Current Bitcoin price hovers around $65,978–$66,000, consolidating in a $60,000–$72,000 range after a 22% decline from last year...
Read more

Top 10 Food Companies by Revenue — 2026 Update

By -
Image
The ten largest food and beverage companies in the world remain Nestle, Ahold Delhaize, PepsiCo., Archer Daniels Midland, Sysco, JBS, Performance Food Group, Anheuser-Busch InBev, Unilever, and Tyson Foods. The global food and beverage industry remains one of the largest and most resilient sectors of the world economy, generating trillions of dollars in annual revenue . While consumer preferences, inflation, and supply-chain realignments continue to reshape the market, a relatively small group of multinational corporations still dominate global food sales. This January 2026 update revises our original 2025 rankings using the latest available full-year 2024 results, 2025 trailing-twelve-month (TTM) data, and confirmed late-2025 corporate developments , including major mergers, recalls, and strategic restructurings.  Top 10 Food Companies by Revenue This ranking reflects the largest companies primarily by annual revenue, emphasizing food production, processing, distri...
Read more

Largest Pharma Companies in the World (2025–2026 Revenue Rankings)

By -
Image
Table of Contents: Largest Pharma Companies by Revenue (Global Ranking) Top 10 Pharmaceutical Companies by Market Cap in 2025 Top 10 Most Anticipated Drug Launches of 2025 Top 10 Drugs Losing US Exclusivity in 2025 The largest pharma companies in the world play a central role in global healthcare, developing blockbuster drugs for cancer, cardiovascular disease, immunology, vaccines, and metabolic disorders. In 2025, the biggest pharmaceutical companies by revenue continued to dominate through scale, research spending, and global distribution—despite growing pressure from patent expirations, biosimilars, and pricing reforms. Medical stocks are releasing earnings reports in droves. Eli Lilly and Co (LLY.US) targets $80 billion in 2026 revenue with standout performance; Novo-Nordisk A/S (NVO.US) beats Q4 expectations but lowers 2026 guidance due to pricing pressures. The largest pharma companies are defined not only by revenue, but by global scale, research investment, and thera...
Read more

AI Demand Drives Ongoing SSD & Memory Shortages: Prices Surging Further into 2026 and Beyond

By -
Image
As we enter 2026, the memory and storage crunch predicted in late 2025 has materialized with even greater intensity. AI data centers continue to dominate global production of DRAM and NAND flash, pushing prices sharply higher and extending lead times across consumer, PC, and enterprise segments. Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM sta...
Read more

NVIDIA vs AMD GPUs for AI: 2026 Comparison and Recommendations

By -
Image
In the rapidly evolving world of AI in 2026, choosing between NVIDIA and AMD GPUs boils down to ecosystem maturity, performance needs, and budget.  NVIDIA GPUs generally lead in AI performance, particularly for short- to medium-term rentals, due to their larger market presence and competitive pricing. However, AMD has been enhancing its offerings and can outperform NVIDIA in certain workloads, so the best choice depends on the specific use case. NVIDIA's dominance stems from its CUDA platform, which powers over 90% of AI frameworks, while AMD is gaining ground with ROCm's open-source approach and cost-effective hardware. AMD's Instinct MI300X and upcoming MI350 series offer competitive inference speeds, sometimes at 40% better efficiency than NVIDIA's Blackwell. This article compares their architectures, benchmarks for AI tasks like training and inference, and provides tailored recommendations with Amazon links for accessible models. Key Differences Between NVIDIA and ...
Read more

5 Best GPUs for AI Video Generation (2026)

By -
Image
As AI video generation tools like Stable Video Diffusion, Runway ML, and emerging models from OpenAI continue to evolve, having the right GPU is crucial for creators, developers, and enthusiasts. In 2026, AI video workflows demand high VRAM for handling large models, efficient tensor cores for acceleration, and robust support for frameworks like PyTorch and TensorFlow. NVIDIA remains the leader due to its CUDA ecosystem, but AMD offers competitive alternatives with improving ROCm support. This guide ranks the best GPUs based on performance, VRAM, power efficiency, and value for AI video tasks such as text-to-video, video upscaling, and style transfer. Key Factors to Consider When Choosing a GPU for AI Video Generation Before diving into recommendations, here's what matters most in 2026: VRAM Capacity : Aim for at least 24GB to run high-resolution models without batching or offloading. Architecture : NVIDIA's Blackwell (RTX 50-series) offers multi-frame generation (MFG) for fast...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more

Top 10 Cancer Drug Companies of 2025

By -
Image
Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...
Read more

Top Silver ETFs to Watch in 2026: What Investors Need to Know (February 2026)

By -
Image
After its outsized gains in 2024–2025, silver experienced a sharp pullback entering February 2026 — a move that surprised many late-cycle buyers but was consistent with historical silver bull markets. This correction was driven by several overlapping factors: Profit-taking after extreme gains , particularly in leveraged and mining-linked products A stronger U.S. dollar and shifting rate expectations , which temporarily pressured precious metals Speculative positioning unwinds , as futures and options markets became crowded Equity market rotation , drawing capital back toward risk assets Importantly, the pullback did not coincide with a collapse in industrial demand or a sudden resolution of supply constraints. As a result, many analysts view the move as a  volatility reset rather th...
Read more